2024
The CUL5 E3 ligase complex negatively regulates central signaling pathways in CD8+ T cells
Liao X, Li W, Zhou H, Rajendran B, Li A, Ren J, Luan Y, Calderwood D, Turk B, Tang W, Liu Y, Wu D. The CUL5 E3 ligase complex negatively regulates central signaling pathways in CD8+ T cells. Nature Communications 2024, 15: 603. PMID: 38242867, PMCID: PMC10798966, DOI: 10.1038/s41467-024-44885-0.Peer-Reviewed Original ResearchConceptsCD8+ T cellsT cellsCancer immunotherapyMouse CD8+ T cellsAnti-tumor immunityTumor growth inhibition abilityAnti-tumor effectsInhibition of neddylationCD8Effector functionsTCR stimulationIL2 signalingCentral signaling pathwaysCore signaling pathwaysEffector activityNegative regulatory mechanismsTranslational implicationsImmunotherapyGrowth inhibition abilityCytokine signalingTCRProteomic alterationsSignaling pathwayCancerCRISPR-based screens
2021
Accelerating precision anti-cancer therapy by time-lapse and label-free 3D tumor slice culture platform
Xing F, Liu Y, Huang S, Lyu X, Su S, Chan U, Wu P, Yan Y, Ai N, Li J, Zhao M, Rajendran B, Liu J, Shao F, Sun H, Choi T, Zhu W, Luo G, Liu S, Xu D, Chan K, Zhao Q, Miao K, Luo K, Ge W, Xu X, Wang G, Liu T, Deng C. Accelerating precision anti-cancer therapy by time-lapse and label-free 3D tumor slice culture platform. Theranostics 2021, 11: 9415-9430. PMID: 34646378, PMCID: PMC8490519, DOI: 10.7150/thno.59533.Peer-Reviewed Original ResearchConceptsAnti-cancer therapyNew pre-clinical modelsDay of surgeryPre-clinical modelsRNA sequence analysisHigh-efficacy drugsAnti-cancer drug efficacyPD-1PD-L1Personalized medicineBlockade assayAnti-cancer drug discoveryImmune componentsOriginal tumorAutofluorescence featuresDrug efficacyHistological analysisPrecision anti-cancer therapyCancer treatmentDrug responseHigh-throughput drug screeningDrug discoveryTherapyEfficacyCell-based high-throughput drug screening